🇺🇸 L-BLP25 in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 11

Most-reported reactions

1. Pulmonary Oedema — 2 reports (18.18%)
2. Alanine Aminotransferase Increased — 1 report (9.09%)
3. Anxiety — 1 report (9.09%)
4. Aspartate Aminotransferase Increased — 1 report (9.09%)
5. Cardiac Arrest — 1 report (9.09%)
6. Cardiac Failure — 1 report (9.09%)
7. Death — 1 report (9.09%)
8. Dehydration — 1 report (9.09%)
9. Embolism — 1 report (9.09%)
10. Hypoalbuminaemia — 1 report (9.09%)

Source database →

Frequently asked questions

Is L-BLP25 approved in United States?

L-BLP25 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for L-BLP25 in United States?

Prof. Dr. Carl Schimanski is the originator. The local marketing authorisation holder may differ — check the official source linked above.